Takeda's Rozerem Substance Abuse/Toxicity Claims Draw FDA Rebuke
This article was originally published in PharmAsia News
Executive Summary
Takeda misrepresents its sleep aid Rozerem (ramelteon) in sales materials aimed at physicians who treat substance abusers by claiming the product has "no likelihood of abuse and no detectable toxicity," FDA's Division of Drug Marketing, Advertising and Communications charges
You may also be interested in...
Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains
TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success
Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains
TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success
Somaxon's Silenor Gains An FDA Approval, But Can The Pharma Afford A Launch?
Somaxon hopes to launch its insomnia drug in the second half of 2010, but is still searching for a U.S. commercial partner.